Novartis AG ADR buy melinda
Start price
25.05.19
/
50%
€79.30
Target price
04.11.21
€90.20
Performance (%)
-8.45%
End price
05.11.21
€72.60
Summary
This prediction ended on 05.11.21 with a price of €72.60. With a performance of -8.45%, the BUY prediction by melinda finished with a loss. Dividends of €5.57 are taken into consideration when calculating the performance. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novartis AG ADR | -3.653% | -3.653% | 14.674% | 42.183% |
iShares Core DAX® | -3.429% | 3.133% | 15.455% | 14.827% |
iShares Nasdaq 100 | -6.121% | -1.433% | 16.794% | 27.167% |
iShares Nikkei 225® | -7.364% | 1.018% | 8.293% | -2.680% |
iShares S&P 500 | -4.366% | 0.247% | 18.541% | 32.687% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Cycadia (sNDA)
décision de la FDA sur Zykadia en première intention - le traitement des patients atteints de cancer du poumon métastatique non à petites cellules (NSCLC) , dont les tumeurs sont kinase lymphatique anaplasique (ALK) - positif
23/08/2017
La FDA approuve l'utilisation prolongée de Zykadia 26, mai 2017
In the thread Trading Novartis AG ADR
Die von melinda gewählte maximale Laufzeit wurde überschritten